Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Agios has FDA-approved mitapivat products, an early AQVESME thalassemia launch and more than $1.0B of cash and marketable securities. The diligence question is whether prescription growth and pipeline catalysts can outpace a quarterly expense base above $130M.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Robo.ai is trying to move from a failed smart-EV revenue base into an AI robotics, intelligent hardware and asset platform. The filings show FY2025 revenue of only $0.95 million, a $167.3 million net loss, $4.1 million of cash, $124.6 million of liabilities, n
OpenAI Infrastructure Acquisition Corp. is a newly public SPAC with $140.5 million in trust, $1.1 million of cash outside trust, no operating revenue, no announced target and an April 6, 2027 deadline. The current thesis is trust math, sponsor incentives and futur
OpenACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
OpenOfficial-source baseline for Abeona Therapeutics using SEC submissions, SEC company facts, the FY2025 10-K, latest available 10-Q, filed FY2025 results release, filed launch update, 2026 proxy materials, and FDA product approval sources.
OpenTag facets appear after tag usage counts are rebuilt.